Beyond Air(US:XAIR)2026-02-13 21:01Product Development and Approval - The LungFit PH system received FDA premarket approval in June 2022 and is indicated for improving oxygenation in neonates with hypoxic respiratory failure associated with pulmonary hypertension [126]. - The company received European CE mark approval for LungFit PH on November 26, 2024, and has since obtained regulatory approvals in over 10 other countries [138]. - The company is developing a proprietary delivery system for ultra-high concentrations of nitric oxide (UNO) for treating solid tumors, currently in phase 1 human clinical trials [128]. - The company has entered into an agreement to acquire commercial rights for nNOS inhibitors targeting autism spectrum disorder (ASD) and other neurological conditions, with development timing under review [130]. Market Potential - The company anticipates U.S. sales potential for LungFit PH to be approximately $350 million and worldwide sales potential to exceed $700 million [139]. - The U.S. market potential for bronchiolitis is estimated to exceed $500 million, while the worldwide market potential is over $1.2 billion [145]. - The U.S. sales potential for Nontuberculous Mycobacteria (NTM) lung infections is projected to be greater than $1 billion, with worldwide sales potential exceeding $2.5 billion [151]. Clinical Trials and Results - The company initiated the first phase of its commercial launch in July 2022 and entered the final phase of the launch process in spring 2023, aiming to become the market leader in the U.S. within a few years [139]. - The pilot clinical trial for the LungFit PRO system showed a trend of shortening length of stay by a factor of 1.8 for patients treated with inhaled NO compared to standard supportive treatment [142]. - The clinical trial for bronchiolitis showed that 150 ppm – 160 ppm NO was safe and effective in shortening hospital length of stay (LOS) and accelerating time to stable oxygen saturation [146]. - The long-term safety data indicated a favorable re-hospitalization rate for bronchiolitis-related reasons in the inhaled NO group compared to control [148]. - Positive interim data from the NTM clinical trial showed high treatment compliance (>90%) and improvement in quality of life and respiratory function [154]. - A case of relapsed/refractory Triple Negative Breast Cancer showed no evidence of malignancy following UNO treatment, indicating potential efficacy [165]. Financial Performance - Revenues for the three months ended December 31, 2025, were $2.2 million, a 104% increase from $1.1 million in the same period of 2024 [173]. - Revenues for the nine months ended December 31, 2025, were $5.8 million, up 126% from $2.6 million in the same period of 2024 [174]. - Gross profit for the three months ended December 31, 2025, was $0.3 million, compared to a gross loss of $0.2 million for the same period in 2024 [173]. - Research and development expenses for the three months ended December 31, 2025, decreased to $2.4 million from $3.0 million in 2024, a reduction of 20% [176]. - Selling, general and administrative expenses for the three months ended December 31, 2025, were $4.5 million, down 43% from $7.7 million in 2024 [178]. - Net loss attributable to common stockholders for the three months ended December 31, 2025, was $7.3 million, or a loss of $0.85 per share, compared to a net loss of $13.0 million, or a loss of $2.96 per share in 2024 [183]. - The company reported a comprehensive loss attributable to Beyond Air, Inc. of $22.8 million for the nine months ended December 31, 2025 [184]. Cash Flow and Funding - Net cash used in operating activities for the nine months ended December 31, 2025, was $13.2 million, primarily due to a net loss of $23.9 million [186]. - For the nine months ended December 31, 2025, net cash used in operating activities was $31.2 million, primarily due to a net loss of $40.4 million [187]. - For the nine months ended December 31, 2025, net cash provided by financing activities was $24.2 million, mainly from the issuance of common stock totaling $8.1 million [190]. - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities of $11.7 million, with an accumulated loss of $309.3 million since inception [192]. - The company expects to incur net losses and cash outflows for at least the next twelve months, indicating a need for additional funding [193]. - On November 1, 2024, the company entered into a Loan and Security Agreement for a secured loan of $11.5 million with a 15% annual interest rate [195]. - On November 4, 2025, the company issued a secured promissory note for $12.0 million, with interest accruing at 15% per annum after the first 12 months [200]. - The company generated revenue of $10.7 million from product sales to date [192]. - The company has experienced a decrease in operating cash flow of $13.2 million for the nine months ended December 31, 2025 [192]. - The company entered into an At-The-Market Offering Sales Agreement allowing for the sale of up to $35.0 million in common stock [197]. - The company is exploring strategic collaborations and licensing agreements to fund operations until sufficient product revenues are generated [205].